Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A recent publication from the Powrie group at the Kennedy Institute of Rheumatology has described a novel mechanism by which the commensal pathogen Heliobacter hepaticus maintains its niche in the intestinal environment.

The work, led by Dr Camille Danne in Prof Fiona Powrie's group, describes the effects of a newly described H. hepaticus secreted polysaccharide on intestinal macrophages, promoting a pro-repair and anti-inflammatory gene signature and effector phenotype.

The discovery of this mechanism provides a better understanding of the potential means of molecular crosstalk between key host cells in the gut and commensal bacteria. By further understanding the pathways that promote tolerance and normal homeostasis, these same pathways can potentially be enhanced in order to restore balance after disruptive challenges and interventions such as antibiotic treatment, stress and food allergy, as well as to re-establish a balanced host–microbe dialogue in chronic inflammation.

The study, carried out in collaboration with Prof Simon Arthur's group in the University of Dundee, was published in Cell Host and Microbe earlier this month and can be accessed here, as was a commentary on the paper from the Kullberg lab which can be found here.

Similar stories

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Welcome to the new Kennedy Trust CEO

The Kennedy Trust has announced Dr Stephen Simpson as its new Chief Executive Officer from 1 July 2022.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.

Defining the role of resident memory B cells in the fight against influenza

Researchers at the Kennedy Institute of Rheumatology have used 3D and live-imaging to show how resident memory B cells boost antibodies to fight influenza.

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

The COVID-19 Multi-omic Blood Atlas (COMBAT) has identified blood hallmarks of COVID-19 involving particular immune cell populations and their development, components of innate and adaptive immunity, and connectivity with the inflammatory response.